NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, January, 30th. The biopharmaceutical company reported $2.71 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.60 by $0.11. The biopharmaceutical company earned $1.38 billion during the quarter, compared to analysts' expectations of $1.32 billion. Alexion Pharmaceuticals had a return on equity of 21.29% and a net margin of 48.17%. Alexion Pharmaceuticals's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.14 EPS. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $10.65-$10.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.50-$5.56 billion, compared to the consensus revenue estimate of $5.51 billion.

20 brokerages have issued 12 month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $131.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $149.95 in the next twelve months. This suggests a possible upside of 51.4% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

News articles about ALXN stock have trended neutral this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Alexion Pharmaceuticals.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), Celgene (CELG), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Biogen (BIIB), Visa (V) and Broadcom (AVGO).

Alexion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wealth Quarterback LLC (6.93%), FMR LLC (6.64%), State Street Corp (4.95%), Renaissance Technologies LLC (1.69%), Artisan Partners Limited Partnership (1.49%) and Geode Capital Management LLC (1.44%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Franklin Resources Inc., Partner Fund Management L.P., FIL Ltd, Sei Investments Co., Jennison Associates LLC and Strs Ohio. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker and Indrani Lall Franchini. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, AQR Capital Management LLC, Renaissance Technologies LLC, Bank of Montreal Can, LSV Asset Management, Thrivent Financial for Lutherans, Man Group plc and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $99.02.

Alexion Pharmaceuticals has a market capitalization of $21.92 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]